TME Pharma NV
ALTME
Company Profile
Business description
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
Contact
Max-Dohrn-Street 8-10
Berlin10589
DEUT: +49 307262470
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,913.90 | 352.20 | 4.66% |
| CAC 40 | 7,188.68 | 325.66 | 4.75% |
| DAX 40 | 20,659.12 | 988.24 | 5.02% |
| Dow JONES (US) | 40,608.45 | 2,962.86 | 7.87% |
| FTSE 100 | 7,999.14 | 319.66 | 4.16% |
| HKSE | 20,681.78 | 417.29 | 2.06% |
| NASDAQ | 17,124.97 | 1,857.06 | 12.16% |
| Nikkei 225 | 34,609.00 | 2,894.97 | 9.13% |
| NZX 50 Index | 12,201.43 | 394.88 | 3.34% |
| S&P 500 | 5,456.90 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,709.60 | 334.60 | 4.54% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |